Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.
Lakhani NJ, Papadopoulos KP, Johnson ML, Park H, Wang D, Yap TA, Dowlati A, Maki RG, Ulahannan S, Lynce F, Kelly K, Williamson S, Malhotra J, Chen S, Gonzalez Ortiz A, Jankovic V, Paccaly A, Masinde S, Mani J, Lowy I, Gullo G, Sims T, Kroog G. Lakhani NJ, et al. Among authors: williamson s. Clin Cancer Res. 2024 Dec 16;30(24):5601-5611. doi: 10.1158/1078-0432.CCR-23-3883. Clin Cancer Res. 2024. PMID: 39422598 Free PMC article. Clinical Trial.
Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer.
Huang CH, Williamson SK, Neupane P, Taylor SA, Allen A, Smart NJ, Uypeckcuat AM, Spencer S, Wick J, Smith H, Van Veldhuizen PJ, Kelly K. Huang CH, et al. Among authors: williamson sk. Front Oncol. 2016 Jan 13;5:301. doi: 10.3389/fonc.2015.00301. eCollection 2015. Front Oncol. 2016. PMID: 26793618 Free PMC article.
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
Oh DY, Maqueda MA, Quinn DI, O'Dwyer PJ, Chau I, Kim SY, Duran I, Castellano D, Berlin J, Mellado B, Williamson SK, Lee KW, Marti F, Mathew P, Saif MW, Wang D, Chong E, Hilger-Rolfe J, Dean JP, Arkenau HT. Oh DY, et al. BMC Cancer. 2023 Nov 3;23(1):1056. doi: 10.1186/s12885-023-11539-1. BMC Cancer. 2023. PMID: 37919668 Free PMC article. Clinical Trial.
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
Sharma P, Abramson VG, O'Dea A, Nye L, Mayer I, Pathak HB, Hoffmann M, Stecklein SR, Elia M, Lewis S, Scott J, De Jong JA, Wang YY, Yoder R, Schwensen K, Finke K, Heldstab J, LaFaver S, Williamson SK, Phadnis MA, Reed GA, Kimler BF, Khan QJ, Godwin AK. Sharma P, et al. Among authors: williamson sk. Clin Cancer Res. 2021 Jul 15;27(14):3896-3904. doi: 10.1158/1078-0432.CCR-20-4879. Epub 2021 Feb 18. Clin Cancer Res. 2021. PMID: 33602685 Free PMC article. Clinical Trial.
1,303 results